Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
Nonhlanhla N. Mkhize, Bo Zhang, Caroline Brackett, Peter Elyanu, Asa Tapley, Sufia Dadabhai, Jiani Hu, Trần Ngọc Bích, Daniel J. Schuster, Jack Heptinstall, Sheetal Sawant, Kelly E. Seaton, Marcella Sarzotti‐Kelsoe, Aaron Hudson, Yutong Jin, Sinethemba Bhebhe, Haajira Kaldine, Prudence Kgagudi, Tandile Modise, Nyaradzo Mgodi, Jessica Andriesen, April K. Randhawa, Leigh H. Fisher, Jia Jin Kee, Craig A. Magaret, James Peng, Avi Kenny, Lindsay N. Carpp, Zhe Chen, Siyu Heng, Manuel Villarán, Azwidihwi Takalani, Bert Le Roux, Eduan Wilkinson, Jackline Odhiambo, Parth D. Shah, Laura Polakowski, Margaret Yacovone, Taraz Samandari, Zvavahera M. Chirenje, Joseph Makhema, Ethel Kamuti, Katanekwa Njekwa, Harriet Nuwagaba‐Biribonwoha, Andrew Baguma, Sharlaa Badal‐Faesen, William Brumskine, Soritha Coetzer, Rodney Dawson, Sinead Delany‐Moretlwe, Andreas H. Diacon, Samantha Fry, Katherine Gill, Anda Madikida, Zaheer Hoosain, Mina C. Hosseinipour, Mubiana Inambao, Craig Innes, Steve Innes, Dishiki Kalonji, Humphrey Mwape, Priya Kassim, Melvin C. Kamanga, William Kilembe, Fatima Laher, Mookho Malahleha, Vongane Louisa Maluleke, Grace Mboya, Philister Adhiambo Madiega, Kirsten McHarry, Essack Mitha, Yajna Duki, Pamela Mda, Moroesi Moerane, Tumelo Moloantoa, Simpson Nuwamanya, Sharana Mahomed, Vimla Naicker, Anusha Nana, Annet Nanvubya, Barbarah Kawoozo, Maphoshane Nchabeleng, Walter Otieno, Elsje Louise Potgieter, Disebo Potloane, Zelda Punt, Jamil Said, Yashna Singh, Sheetal Kassim, Dorothie van der Vendt, Mohammed Siddique Tayob, Yacoob Vahed, Deo Wabwire, James G. Kublin, Linda‐Gail Bekker, Lawrence Corey, Glenda Gray, Yunda Huang, Philip Kotze, Nigel GarrettNature Communications2025 · DOI
People with HIV (PWH) are understudied in COVID-19 vaccine trials, leaving knowledge gaps on whether the identified immune correlates of protection also hold in PWH. CoVPN 3008 (NCT05168813) enrolled predominantly PWH and reported lower COVID-19 incidence for a Hybrid vs. Vaccine Group (baseline SARS-CoV-2-positive and one mRNA-1273 dose vs. negative and two doses). Using case-cohort sampling, antibody markers at enrolment (M0) and four weeks post-final vaccination (Peak) are assessed as immune correlates of COVID-19. For the Hybrid Group [n = 287 (195 PWH)], all M0 markers inversely correlate with COVID-19 through 230 days post-Peak, with 50% inhibitory dilution BA.4/5 neutralizing antibody titer (nAb-ID50 BA.4/5) the strongest and only independent correlate (HR per 10-fold increase=0.46, 95% CI 0.28, 0.75; P = 0.002). For the Vaccine Group [n = 115 (86 PWH)], Peak nAb-ID50 BA.4/5 correlates with reduced COVID-19 risk (1.9%, 1.1%, and 0.3% at titers 10, 100, and 1000 AU/ml) through 92, but not 165, days post-Peak. Using multivariable Cox analysis of binding and nAb, nAb titers predict COVID-19 in PWH. Two doses of a 100-µg Ancestral strain mRNA vaccine in baseline-SARS-CoV-2-negative individuals elicit sufficient cross-reacting Omicron antibodies to reduce COVID-19 incidence for 90 days post-Peak, but viral evolution and waning antibodies abrogate this protection thereafter.
Introduction
People with HIV (PWH) have historically been underrepresented in large-scale COVID-19 vaccine trials, creating a significant knowledge gap regarding whether established immune correlates of protection apply to this population. As SARS-CoV-2 evolved into the Omicron lineage, the effectiveness of original ancestral strain vaccines became a critical question. The CoVPN 3008 (Ubuntu) study sought to address these gaps by evaluating antibody markers as correlates of risk in a predominantly African population with a high prevalence of HIV, comparing those with "hybrid immunity" (prior infection plus vaccination) to those receiving a standard two-dose vaccine regimen.
Methods
The study utilized a case-cohort sampling design from the CoVPN 3008 clinical trial (NCT05168813), which enrolled 11,697 participants, 83% of whom were PWH. Researchers measured antibody markers at enrolment (M0) and four weeks post-final vaccination (Peak). Primary markers included IgG binding antibodies (bAb) against the Nucleocapsid (N) and Spike (BA.4/5) proteins, and neutralizing antibodies (nAb) measured as the 50% inhibitory dilution (ID50) against Omicron BA.4/5. Multivariable Cox proportional hazards models, adjusted for variables such as age, sex, BMI, and HIV status, were used to determine if these markers independently predicted symptomatic COVID-19 risk.
Results
The Hybrid Immunity Advantage
Participants with prior infection who received one vaccine dose (Hybrid Group) demonstrated significantly higher and more durable antibody levels compared to previously uninfected individuals receiving two doses (Vaccine Group). In the Hybrid Group, neutralizing antibody titers against BA.4/5 at enrolment (M0) were the strongest independent predictor of risk. A 10-fold increase in these antibodies reduced the risk of infection by more than half (Hazard Ratio = 0.46).
Neutralizing antibody titers (nAb-ID50 BA.4/5) at enrolment (M0) for Hybrid and Vaccine groups, stratified by HIV status.
In the Vaccine Group, protection was highly time-dependent. While peak antibody levels correlated with significantly reduced risk for the first 90 days post-vaccination (e.g., 1.9% risk at a titer of 10 vs. 0.3% risk at a titer of 1000), this protection vanished by day 165. This suggests that while ancestral strain vaccines elicit cross-reactive antibodies capable of neutralizing Omicron briefly, they lack the long-term durability observed in hybrid immunity.
Peak neutralizing antibody titers (nAb-ID50 BA.4/5) four weeks post-final vaccination, showing responses across study groups.
Encouragingly, PWH with well-controlled viral loads on antiretroviral therapy exhibited immune responses and correlate patterns very similar to people without HIV (PWoH). This indicates that established immune benchmarks are globally applicable across different populations regardless of HIV status, provided the infection is well-managed.
Discussion
The CoVPN 3008 study confirms that neutralizing and binding antibodies are reliable correlates of risk for COVID-19 in PWH, mirroring patterns seen in the general population. The findings highlight that hybrid immunity provides robust, long-lasting protection, whereas two doses of mRNA vaccine in naive individuals offer only transient protection against Omicron subvariants. Limitations of the study include the lack of a placebo arm and a primary focus on humoral immunity rather than T-cell responses. Future research is needed to evaluate how newer, variant-specific booster vaccines perform as immune correlates in PWH.
Summary updated
Abstract
People with HIV (PWH) are understudied in COVID-19 vaccine trials, leaving knowledge gaps on whether the identified immune correlates of protection also hold in PWH. CoVPN 3008 (NCT05168813) enrolled predominantly PWH and reported lower COVID-19 incidence for a Hybrid vs. Vaccine Group (baseline SARS-CoV-2-positive and one mRNA-1273 dose vs. negative and two doses). Using case-cohort sampling, antibody markers at enrolment (M0) and four weeks post-final vaccination (Peak) are assessed as immune correlates of COVID-19. For the Hybrid Group [n = 287 (195 PWH)], all M0 markers inversely correlate with COVID-19 through 230 days post-Peak, with 50% inhibitory dilution BA.4/5 neutralizing antibody titer (nAb-ID50 BA.4/5) the strongest and only independent correlate (HR per 10-fold increase=0.46, 95% CI 0.28, 0.75; P = 0.002). For the Vaccine Group [n = 115 (86 PWH)], Peak nAb-ID50 BA.4/5 correlates with reduced COVID-19 risk (1.9%, 1.1%, and 0.3% at titers 10, 100, and 1000 AU/ml) through 92, but not 165, days post-Peak. Using multivariable Cox analysis of binding and nAb, nAb titers predict COVID-19 in PWH. Two doses of a 100-µg Ancestral strain mRNA vaccine in baseline-SARS-CoV-2-negative individuals elicit sufficient cross-reacting Omicron antibodies to reduce COVID-19 incidence for 90 days post-Peak, but viral evolution and waning antibodies abrogate this protection thereafter.
BibTeX
@inproceedings{mkhize2025neutralizing,
author = {Nonhlanhla N. Mkhize and Bo Zhang and Caroline Brackett and Peter Elyanu and Asa Tapley and Sufia Dadabhai and Jiani Hu and Trần Ngọc Bích and Daniel J. Schuster and Jack Heptinstall and Sheetal Sawant and Kelly E. Seaton and Marcella Sarzotti‐Kelsoe and Aaron Hudson and Yutong Jin and Sinethemba Bhebhe and Haajira Kaldine and Prudence Kgagudi and Tandile Modise and Nyaradzo Mgodi and Jessica Andriesen and April K. Randhawa and Leigh H. Fisher and Jia Jin Kee and Craig A. Magaret and James Peng and Avi Kenny and Lindsay N. Carpp and Zhe Chen and Siyu Heng and Manuel Villarán and Azwidihwi Takalani and Bert Le Roux and Eduan Wilkinson and Jackline Odhiambo and Parth D. Shah and Laura Polakowski and Margaret Yacovone and Taraz Samandari and Zvavahera M. Chirenje and Joseph Makhema and Ethel Kamuti and Katanekwa Njekwa and Harriet Nuwagaba‐Biribonwoha and Andrew Baguma and Sharlaa Badal‐Faesen and William Brumskine and Soritha Coetzer and Rodney Dawson and Sinead Delany‐Moretlwe and Andreas H. Diacon and Samantha Fry and Katherine Gill and Anda Madikida and Zaheer Hoosain and Mina C. Hosseinipour and Mubiana Inambao and Craig Innes and Steve Innes and Dishiki Kalonji and Humphrey Mwape and Priya Kassim and Melvin C. Kamanga and William Kilembe and Fatima Laher and Mookho Malahleha and Vongane Louisa Maluleke and Grace Mboya and Philister Adhiambo Madiega and Kirsten McHarry and Essack Mitha and Yajna Duki and Pamela Mda and Moroesi Moerane and Tumelo Moloantoa and Simpson Nuwamanya and Sharana Mahomed and Vimla Naicker and Anusha Nana and Annet Nanvubya and Barbarah Kawoozo and Maphoshane Nchabeleng and Walter Otieno and Elsje Louise Potgieter and Disebo Potloane and Zelda Punt and Jamil Said and Yashna Singh and Sheetal Kassim and Dorothie van der Vendt and Mohammed Siddique Tayob and Yacoob Vahed and Deo Wabwire and James G. Kublin and Linda‐Gail Bekker and Lawrence Corey and Glenda Gray and Yunda Huang and Philip Kotze and Nigel Garrett},
title = {{Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV}},
booktitle = {Nature Communications},
year = {2025},
doi = {10.1038/s41467-025-63948-4},
}